Phase II Study Evaluating Safety and Efficacy of Tislelizumab for Elderly Patients Unfit for Chemotherapy, With Advanced Esophageal Squamous-cell Carcinoma

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

PHASE2

Total Enrollment

95 participants

Study Classification

INTERVENTIONAL

Study Start Date

2025-10-07

Study Completion Date

2030-10-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The goal of this clinical trial is to assess the percentage of patients alive at 6 months in elderly patients, not eligible to an platinum-based chemotherapy, but who can received the Tislelizumab treatment alone as first-line treatment for an advanced esophageal squamous-cell carcinoma (ESCC).

Tislelizumab is a monoclonal antibody administred by intravenous infusion

This study aims to anwer too at the questions:

* the Safety of the drug
* Overall survival (OS) at 6 months according the diagnostic of PD-L1 expression (PD-L1 is a protein present on the surface of immune cells)
* Overall response rate (ORR) according to imagery criteria
* Progression-free survival (PFS) at 3 and 6 months according to imagery criteria and depending on PDL1 expression
* Patients' health-related quality of life
* OS and PFS according to geriatric parameters
* Prognostic value of immune biomarkers

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Study of Tislelizumab Combined With Chemoradiotherapy and Surgery for Unresectable Esophageal Squamous Cell Carcinoma

NCT07039162

Esophageal Squamous Cell Carcinoma (ESCC) Locally Advanced Unresectable Esophageal Cancer

RECRUITING PHASE2

A Study of Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma

NCT03430843

Esophageal Squamous Cell Carcinoma (ESCC)

COMPLETED PHASE3

Conversion of Tislelizumab Combined With Chemotherapy in Unresectable Esophageal Squamous Cell Carcinoma

NCT05449483

Esophageal Squamous Cell Carcinoma by AJCC V8 Stage Unresectable

UNKNOWN PHASE2

Neoadjuvant Immunochemotherapy for Adenocarcinoma of the Esophagogastric Junction

NCT06469060

Esophageal Cancer

NOT_YET_RECRUITING PHASE2

Induction Tislelizumab Combined With Chemotherapy Followed by Definitive Chemoradiotherapy in the Treatment of Locally Unresectable Esophageal Squamous Cell Carcinoma

NCT05515315

Immunotherapy Esophagus Cancer

RECRUITING PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is a multicenter open-label single arm phase II study to evaluate Tislelizumab in monotherapy in frontline metastatic or locally advanced ESCC.

Patient aged ≥70 years will be selected for inclusion after a diagnosis of metastatic or locally advanced ESCC, and if they are not eligible for a platinum-based chemotherapy regimen.

Tislelizumab (200 mg flat dose every 3 weeks) will be received by intravenous perfusion until progression or unacceptable toxicity, for a maximum of 2 years.

The patients will be included regardless of PD-L1 status; A comparison for all study population will be carried out centrally as part of the ancillary enquiries.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Esophageal Squamous Cell Carcinoma (ESCC)

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

all patients receive the Tislelizumab on monotherapy

Group Type EXPERIMENTAL

Tislelizumab is a fully humanized monoclonal antibody specific for human PD-1

Intervention Type DRUG

It is the first study which evaluate efficacy and safety of anti PD-1 immune checkpoint inhibitor alone in the first-line treatment of elderly esophageal squamous-cell carcinoma patients who no fit to received chemotherapy with platine

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Tislelizumab is a fully humanized monoclonal antibody specific for human PD-1

It is the first study which evaluate efficacy and safety of anti PD-1 immune checkpoint inhibitor alone in the first-line treatment of elderly esophageal squamous-cell carcinoma patients who no fit to received chemotherapy with platine

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Histologically proven esophageal squamous cell carcinoma (ESCC)
* Metastatic or locally advanced cancer
* Absence of previous treatment (immunotherapy, chemotherapy or radiotherapy) in first line setting
* Ineligibility for a platinum-based chemotherapy assessed by oncologist and geriatrician
* At least one evaluable and/or measurable lesion as defined by RECIST v1.1 criteria
* Patients ≥ 70 years
* Subjects with WHO performance status ≤ 2
* Estimated life expectancy \>3 months
* Adjuvant therapy finished \>6 months
* Adequate marrow and organ functions defined as:

* Absolute neutrophil count (ANC) ≥ 1 × 109/L,
* Platelet count ≥ 75 × 109/L,
* Hemoglobin ≥ 90 g/L,
* Aspartate transaminase (AST) and alanine transaminase (ALT) ≤ 3 × ULN, or AST and ALT ≤5 ×ULN for patients with liver metastases
* ALP ≤ 5 x ULN unless liver metastases are present, in which case it must be ≤ 10x ULN
* Measured creatinine clearance (CL) \> 40 mL/min (MDRD method)
* Male patients must use a condom during treatment and for 6 months after the last dose when having sexual intercourse with a pregnant woman or with a woman of childbearing potential. Female partners of male patients should also use a highly effective form of contraception if they are of childbearing potential during treatment and for 6 months after the last dose.
* Patient is willing and able to comply with the protocol for the duration of the study including undergoing treatment, scheduled visits and examinations including follow up.
* Signed written informed consent obtained prior to any study specific procedures
* Patient affiliated to a social security scheme

Exclusion Criteria

* History of another primary malignancy. May be included, patients with:

* Malignancy treated with curative intent and with no known active disease ≥ 2 years before the first dose of treatment
* Adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease
* Adequately treated carcinoma in situ without evidence of disease
* Locally advanced esophageal carcinoma that is resectable or potentially curable with radiation therapy per local investigator
* Participation in another clinical study with an investigational product during the last 2 months.
* Concurrent enrolment in another clinical study unless it is an observational (non-interventional) clinical study or during the follow-up period of an interventional study.
* History of allogenic organ, bone marrow, or double umbilical cord blood transplantation
* Active documented autoimmune or inflammatory disorders (including inflammatory bowel disease \[e.g., colitis or Crohn's disease\], systemic lupus erythematosus, Sarcoidosis syndrome, or Wegener syndrome \[granulomatosis with polyangiitis, Graves' disease, rheumatoid arthritis, hypophysitis, uveitis, etc\]). May be included:

* Patients with vitiligo or alopecia
* Patients with hypothyroidism (e.g., following Hashimoto syndrome) stable on hormone replacement.
* Any chronic skin condition that does not require systemic therapy.
* Patients with celiac disease controlled by diet alone
* Previous immune checkpoint inhibitor therapy within the 2 years before inclusion
* Uncontrolled intercurrent illness; uncontrollable pleural effusion, pericardial effusion, or ascites requiring frequent drainage or medical intervention (recurrence ≤ 14 days after intervention). Patients with the following diseases are not excluded and may proceed to further screening:

* Controlled Type I diabetes
* Hypothyroidism (provided it is managed with hormone replacement therapy only)
* Controlled celiac disease
* Skin diseases not requiring systemic treatment (eg, vitiligo, psoriasis, alopecia)
* Any other disease that is not expected to recur in the absence of external triggering factors
* Patients with evidence of fistula (either oesophageal/bronchial or oesophageal/aorta)
* Patients considered at poor medical risk due to a serious, uncontrolled medical disorder, non-malignant systemic disease, or active, uncontrolled ventricular arrhythmia, recent (within 6 months) myocardial infarction, pulmonary embolism/deep vein thrombosis, cerebrovascular accident, and heart failure, uncontrolled major seizure disorder, unstable spinal cord compression, superior vena cava syndrome, interstitial bilateral lung disease on high Resolution Computed Tomography (HRCT) scan or any psychiatric disorder that prohibits obtaining informed consent. Underlying medical conditions (including laboratory abnormalities) or alcohol or drug abuse or dependence that will be unfavorable for the administration of study drug or affect the explanation of drug toxicity or AEs or might impair compliance with study conduct. A history of severe hypersensitivity reactions to other monoclonal antibodies. Has received any chemotherapy, immunotherapy (eg, interleukin, interferon, thymosin, etc) or any investigational therapies within 14 days or 5 half-lives (whichever is shorter) of the first study drug administration.
* Patients with myelodysplastic syndrome/acute myeloid leukaemia or with features suggestive of MDS/AML.
* Patient with symptomatic central nervous system (CNS) metastases.
* History of active primary immunodeficiency.
* Known non-controlled serologically positive human immunodeficiency virus (HIV) patients with CD4 \< 400 / mm3.
* Active infection including tuberculosis (clinical evaluation that includes clinical history, physical examination and radiographic findings, and TB testing in line with local practice), active untreated hepatitis B (known positive HBV surface antigen (HBsAg) result), active untreated hepatitis C. Patients with a past or resolved HBV infection (defined as the presence of hepatitis B core antibody \[anti-HBc\] and absence of HBsAg) are eligible. Patients positive for hepatitis C (HCV) antibody are eligible only if polymerase chain reaction is negative for HCV RNA.
* Current or prior use of immunosuppressive medication within 14 days before the first dose of -immunotherapy. The following are exceptions to this criterion:

* Intranasal, inhaled, topical steroids, or local steroid injections (e.g., intra articular injection)
* Systemic corticosteroids at physiologic doses not to exceed 10 mg/day of prednisone or its equivalent
* Steroids as premedication for hypersensitivity reactions (e.g., CT scan premedication)
* Receipt of live attenuated vaccine within 30 days prior to the first dose of ICI
* Follow-up impossible, according to investigator's decision
* Any psychological, familial, sociological, or geographical condition potentially hampering compliance with the study protocol or follow-up schedule
* Persons i) deprived of liberty by judicial or administrative decision, persons subject to psychiatric care under Articles L. 3212-1 and L. 3213-1 who do not fall under the provisions of Article L. 1121-8 and persons admitted to a health or social care facility for purposes other than research, and (ii) adults subject to a legal protection measure or unable to express their consent (Article L1121-8)

Minimum Eligible Age

70 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No